

Wednesday, October 22nd, 2014

LSC 3 - Life Sciences Centre

2350 Health Sciences Mall

12-1pm



Dr. Annette von Drygalski

Director

Hemophilia and Thrombosis Treatment Center

University of California, San Diego

“^{super}FVa

An Engineered Prohemostatic Agent for Hemophilia and Other Severe Bleeding Situations”

The topic of this talk will be ^{super}FVa, a novel prohemostatic FVa variant with enhanced biological activity and APC resistance. ^{super}FV was engineered with mutations of 3 activated protein C (APC) cleavage sites and a disulfide bond between the A2 and A3 domains. Data demonstrating this molecule’s excellent prohemostatic properties in hemophilic bleeding and other bleeding severe bleeding situations will be presented.

Sponsored by:



Bayer HealthCare